ArticleAnnals of the rheumatic diseases2000
Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex.
Article in Annals of the rheumatic diseases, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 53 citations in OpenAlex.
- E-cadherin activating antibodies limit barrier dysfunction and inflammation in mouse inflammatory bowel disease.Tissue barriers · 2021Article
- Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment.World journal of gastroenterology · 2019Review
- Histopathological features of gastrointestinal mucosal biopsies in children with juvenile idiopathic arthritis.Pediatric research · 2016Article
- The role of the gut and microbes in the pathogenesis of spondyloarthritis.Best practice & research. Clinical rheumatology · 2014Review
- Current issues in pediatric inflammatory bowel disease-associated arthropathies.World journal of gastroenterology · 2014Review
- Rheumatic manifestations of inflammatory bowel disease.World journal of gastroenterology · 2009Review
- Clinical observations programme in SpA: disease parameters, treatment options and practical management issues.Rheumatology international · 2009Review
- Altered gut transcriptome in spondyloarthropathy.Annals of the rheumatic diseases · 2006Article
- CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease.Annals of the rheumatic diseases · 2005Article
- Gut inflammation in the spondyloarthropathies.Current rheumatology reports · 2005Review
- Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease.Annals of the rheumatic diseases · 2004Article
- Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis.Drugs · 2004Review
- Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy.Annals of the rheumatic diseases · 2003Article
- Gut inflammation and spondyloarthropathies.Current rheumatology reports · 2002Review
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePreviously an upregulation of E-cadherin and its associated molecules alpha-catenin, beta-catenin and plakoglobin has been demonstrated in clinically overt inflammatory bowel disease (IBD). The aim of this study was to investigate the expression of the E-cadherin/catenin complex in subclinically inflamed bowel mucosa from spondyloarthropathy (SpA) patients.
methodsIleal and colonic biopsy specimens from 19 SpA patients with subclinical inflammatory gut lesions and from seven controls were stained with monoclonal antibodies against E-cadherin, beta-catenin and plakoglobin and a polyclonal antibody against alpha-catenin. E-cadherin mRNA was detected using a riboprobe. Inflammation was histologically classified into acute, chronic active and chronic quiescent forms.
resultsIn acute and chronic active bowel inflammation of SpA patients, upregulation of the E-cadherin/catenin glycoprotein complex could be observed. Chronic lesions in a quiescent state did not show such an upregulation. Furthermore, chronic inflammation was associated with an increase in E-cadherin mRNA.
conclusionsAs some of the SpA patients with subclinical gut inflammation develop IBD, upregulation of the E-cadherin/catenin complex in inflamed bowel mucosa from SpA patients may point to early cellular changes in the development of IBD. However, at present it cannot be excluded that increased E-cadherin/catenin complex expression is a bystander phenomenon of active inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.